MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented at the ...

Santos is nearing a major commitment to a large new LNG project next year amid nervousness about a softening in global gas prices and worries about the cost of an investment that was last put at more ...

The establishment of an NRL team in PNG has received global support as the teenage son of one of the nation's greatest players prepares to make his debut. Cooper Bai, whose father Marcus won a ...

Why it matters: For decades, JPEG, PNG, and GIF have remained among the most popular image formats, even as newer options like WebP and AVIF have emerged. Now, PNG is getting its first meaningful ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 ...

Add Yahoo as a preferred source to see more of our stories on Google. It appears that the Mount Vernon school board has finally fired former Superintendent Waveline Bennett-Conroy, who was reassigned, ...

Merck, known as MSD outside of the United States and Canada, announced results from the dose confirmation portion of the phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin in combination ...

Merck MRK announced encouraging data from the dose confirmation portion of the phase II/III waveLINE-003 study evaluating its first-in-class antibody drug conjugate (ADC), zilovertamab vedotin, for ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study ...

RAHWAY, N.J., May 30, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 ...

Multi-virus specific T cells to enhance the activity of bispecific antibodies in lymphoma. Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx ...